Recombinant Escherichia coli Porphobilinogen deaminase (hemC)

Enzyme Structure and Molecular Properties

Recombinant E. coli PBGD is a monomeric protein with a molecular weight of ~34 kDa, confirmed by SDS-PAGE and gene-derived calculations . Key structural features include:

• Active-site dipyrromethane (DPM) cofactor: Covalently linked to a conserved cysteine residue (Cys-262), enabling sequential PBG binding and polymerization .

• Domains: Two flexible domains connected by hinge regions that accommodate the growing polypyrrole chain during catalysis .

• Thermostability: The enzyme retains 86% activity after 1 hour at 70°C (in Clostridium josui homologs) , though E. coli PBGD has an optimal temperature of 37°C .

Table 1: Biophysical and Catalytic Properties of Recombinant PBGD

Catalytic Mechanism and Dynamics

PBGD operates via a processive mechanism involving three intermediate complexes (ES, ES₂, ES₃) during chain elongation . Molecular dynamics simulations reveal:

• Domain flexibility: Domains 1 and 2 move apart to accommodate the growing pyrrole chain, while the active-site loop (residues 50–70) modulates substrate binding .

• Key catalytic residues:

  • D84 and R176: Stabilize the DPM cofactor and deprotonate intermediates .

  • K55: Facilitates substrate orientation and chain elongation .

• Exit mechanism: HMB exits via a cleft between domains 1 and 2, guided by residues R11 and Q19 .

Recombinant Production and Purification

Recombinant PBGD is overproduced in E. coli strains harboring plasmid-borne hemC genes. Key steps include:

• Purification: Affinity chromatography and crystallization yield enzyme with >95% purity (specific activity: 3.3 µmol/h/mg) .

• Crystallization: Achieved using polyethylene glycol precipitant, enabling X-ray diffraction studies .

Table 2: Purification Metrics from Select Studies

Enzyme Replacement Therapy

Recombinant PBGD linked to apolipoprotein A-I (ApoAI-PBGD) shows promise for treating acute intermittent porphyria (AIP). In murine models:

• Liver and brain uptake: Enhanced by ApoAI-mediated targeting, reducing PBG accumulation by >75% .

• Symptom alleviation: Reduced neuropathy and pain in AIP mice .

Metabolic Engineering

PBGD overexpression in E. coli improves heme pathway flux for porphyrin-derived compound synthesis (e.g., biliverdin) .

Recent Advances and Challenges

• Structural insights: Cryo-EM studies reveal conformational changes during HMB release .

• Thermostable variants: C. josui PBGD retains activity at 65°C, suggesting industrial potential .

• Unresolved questions: Substrate entry mechanisms and cofactor regeneration remain under investigation .

Comparative Analysis with Homologs

Table 3: PBGD Homologs Across Species

Future Directions

• Gene therapy: Viral vectors delivering hemC for AIP treatment .

• Industrial biocatalysis: Engineering PBGD for high-temperature tetrapyrrole synthesis .